1. Search Result
Search Result
Results for "

GP120

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

9

Peptides

6

Inhibitory Antibodies

2

Natural
Products

11

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS06977

    H4P; IHRP; GP120; PK120; ITIHL1; PK-120; ITI-HC4

    Small Interfering RNA (siRNA) Others

    ITIH4 Human Pre-designed siRNA Set A contains three designed siRNAs for ITIH4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ITIH4 Human Pre-designed siRNA Set A
    ITIH4 Human Pre-designed siRNA Set A
  • HY-P4055

    HIV Infection Inflammation/Immunology
    GP120, HIV-1 MN is a peptide. GP120, HIV-1 MN can be used for the research of HIV infection .
    GP120, HIV-1 MN
  • HY-144730

    HIV Inflammation/Immunology
    gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an IC50 of 2.2 µM and CC50 of 100.90 µM. gp120-IN-1 shows anti-HIV-1 activity. gp120-IN-1 shows cytotoxicity in a dose dependent manner in SUP-T1 cells. gp120-IN-1 shows inhibition of gp120-mediated virus enter into cells .
    gp120-IN-1
  • HY-144731

    HIV Inflammation/Immunology
    gp120-IN-2 (compound 4i) is a potent HIV-1 gp120 inhibitor with an IC50 of 7.5 µM and CC50 of 112.93 µM. gp120-IN-2 shows anti-HIV-1 activity. gp120-IN-2 shows cytotoxicity in a dose dependent manner in SUP-T1 cells .
    gp120-IN-2
  • HY-164675

    HIV Infection
    gp120-IN-3 (Compound 11) is a HIV-1 gp120 inhibitor with an IC50 value of 1.64 nM, which can be utilized in HIV research .
    gp120-IN-3
  • HY-P10249

    HIV Inflammation/Immunology
    HIV gp120 254-274 is a conserved fragment in envelope glycoprotein gp120 of human immunodeficiency virus (HIV), and exhibits immunosilent activity .
    HIV gp120 (254-274)
  • HY-P990874

    HIV Infection
    Anti-HIV gp120 Antibody (55-36) is a kind of mouse IgG1κ chimeric antibody, targeting to HIV gp120. The recommend isotype control of Anti-HIV gp120 Antibody (55-36): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-HIV gp120 Antibody (55-36)
  • HY-P10251

    HIV Infection
    HIV gp120 (318-327) is a short sequence of the HIV-1 strain IIIB envelope peptide (rgpgrafvti) that corresponds to the conserved C-terminal region of the glycoprotein. HIV gp120 (318-327) is part of the HIV vaccine V3 peptide epitope, also known as the I10 peptide. However, HIV gp120 (318-327) lacks the A2 anchor residues recognized by epitope-specific CTLs but has structural features that confer promiscuous A2 binding .
    HIV gp120 (318-327)
  • HY-P10250

    HIV Inflammation/Immunology
    HIV gp120 308-331 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .
    HIV gp120 (308-331)
  • HY-P10252

    HIV Inflammation/Immunology
    HIV gp120 421-438 is HIV antigen fragments, that conjugates with keyhole limpet hemocyanin (KLH) and generates specific anti-HIV antibody .
    HIV gp120 (421-438)
  • HY-P3554

    HIV Infection
    Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl (compound (CPF(LL)) is an HIV-1 inhibitor. Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl interacts with gp120 to block gp120 binding to CD4 and preserve CD4-dependent T cell function .
    Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl
  • HY-P991064

    3BNC-117

    HIV Infection
    Lafuvitug (3BNC-117) is a fully human IgG1 antibody that targets envelope glycoprotein gp120 protein. The isotype control for Lafuvitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    Lafuvitug
  • HY-76648

    HIV Infection
    NBD-556, a CD4 mimetic, is a potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 shows potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels .
    NBD-556
  • HY-14134
    BMS-378806
    5 Publications Verification

    BMS-806

    HIV Infection
    BMS-378806 is a potent HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. BMS-378806 selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
    BMS-378806
  • HY-P99102

    10-1074

    HIV Infection
    Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) .
    Zinlirvimab
  • HY-119202

    (S)-BMS-806

    HIV Infection
    (S)-BMS-378806 ((S)-BMS-806) is an orally bioavailable HIV-1 inhibitor with activity against gp120-CD4 interactions. (S)-BMS-378806 exhibits micromolar inhibition of HIV-1 gp120-CD4 binding. The design and synthesis of (S)-BMS-378806 was based on a comprehensive study of protein-ligand interactions, which guided the identification and design of novel symmetrical N,N'-disubstituted aminoureas and thioureas. (S)-BMS-378806, synthesized in aqueous media using microwave irradiation, was validated for its inhibitory activity in HIV-1 gp120-CD4 capture ELISA .
    (S)-BMS-378806
  • HY-P991069

    HIV Infection
    VRC-01 is a fully human IgG1 antibody that targets envelope glycoprotein gp120 Protein. VRC-01 blocks viral entry by partially mimicking the interaction of the CD4 receptor with HIV-1 gp120 envelope glycoprotein. The isotype control for VRC-01 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    VRC-01
  • HY-139985

    HIV Infection
    NBD-14189 is a potent HIV-1 entry antagonist with an IC50 of 89 nM against the HIV-1HXB2 pseudovirus. NBD-14189 binds to HIV-1 gp120 and shows potent antiviral activity (EC50<200 nM) .
    NBD-14189
  • HY-125183

    HIV Infection
    BMS-818251 is a potent, small-molecule inhibitor of HIV-1 entry with an EC50 value of 0.019 nM. BMS-818251 shows >10-fold higher potency than BMS-626529 (HY-15440) on a cross-clade panel of 208-HIV-1 strains. BMS-818251 interacts with gp120 residues from the conserved β20-β21 hairpin to improve potency .
    BMS-818251
  • HY-P991479

    HIV Cancer
    GS-8588 is a human bispecific antibody (bsAb) targeting gp120/Glycoprotein 120. GS-8588 induces T cell activation and cytokine secretion in PWH. GS-8588 can be used in AIDS research .
    GS-8588
  • HY-15440
    Temsavir
    4 Publications Verification

    BMS-626529

    HIV Infection
    Temsavir (BMS-626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
    Temsavir
  • HY-N5179

    HIV Infection
    Chloropeptin II inhibits the binding of gp120 to CD4 with IC50 of 3.3 μM, with the activity of selective anti-human immunodeficiency virus (HIV) .
    Chloropeptin II
  • HY-N5178

    HIV Infection
    Chloropeptin I inhibits the binding of gp120 to CD4 with IC50 of 2.0 μM, with the activity of selective anti-human immunodeficiency virus (HIV) .
    Chloropeptin I
  • HY-139989

    HIV Infection
    NBD-14270, a pyridine analogue, is a potent HIV-1 entry antagonist with an IC50 of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC50>100 μM) .
    NBD-14270
  • HY-P0272

    HIV Infection
    Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
    Peptide T
  • HY-P0272A

    HIV Infection
    Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
    Peptide T TFA
  • HY-15440A

    BMS-663068

    HIV Infection
    Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
    Fostemsavir
  • HY-123902

    Zizanin A

    CCR HIV Infection
    Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells . Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells .
    Ophiobolin C
  • HY-15440B

    BMS-663068 Tris

    HIV Infection
    Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl proagent of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
    Fostemsavir Tris
  • HY-15440AR

    BMS-663068 (Standard)

    Reference Standards HIV Infection
    Fostemsavir (Standard) is the analytical standard of Fostemsavir. This product is intended for research and analytical applications. Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
    Fostemsavir (Standard)
  • HY-15440AS

    BMS-663068-d8

    Isotope-Labeled Compounds HIV Infection
    Fostemsavir-d8 (BMS-663068-d8) is deuterium labeled Fostemsavir. Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
    Fostemsavir-d8
  • HY-121820

    HIV Infection
    DMJ-I-228 is a CD4-mimetic. DMJ-I-228 binds to HIV-1 gp120 within the conserved Phe 43 cavity near the CD4-binding site, thereby blocking CD4 binding and inhibiting HIV-1 infection .
    DMJ-I-228
  • HY-P4902

    P-glycoprotein HIV Infection
    Retrocyclin-1 is a kind of Theta-defensin. Retrocyclin-1 recognizes and binds to carbohydrate-containing surface molecules, to protect cells from HIV-1 infection. Retrocyclin-1 exhibits high affinity to fetuin, gp120 (Kd=35.4 nM), CD4 (Kd=31 nM), and galactosylceramide (Kd=24.1 nM) .
    Retrocyclin-1
  • HY-120427

    NSC 658586

    CCR CXCR HIV HSV Infection Inflammation/Immunology
    Cosalane (NSC 658586) is a CCR7 (IC50 = 2.43 μM) and CXCR2 antagonist (IC50 = 0.66 μM). Cosalane is an inhibitor of HIV replication with a wide range of activity against HIV-1 isolates, HIV-2, Rauscher murine leukemia virus, HSV-1, HSV-2 and human cytomegalovirus. Cosalane inhibits both attachment of gp120 to CD4. Cosalane inhibits human and murine CCR7 in response to both CCL19 and CCL21 agonists. Cosalane can be studied in research for HIV or attenuating acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) .
    Cosalane
  • HY-123756

    HIV Infection
    NBD-10007 is a CD4 agonist. NBD-10007 has anti-HIV-1 viral activity .
    NBD-10007

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: